WO2011070045A1 - Anticorps monoclonaux contre la protéine rgm a destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes - Google Patents

Anticorps monoclonaux contre la protéine rgm a destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes Download PDF

Info

Publication number
WO2011070045A1
WO2011070045A1 PCT/EP2010/069120 EP2010069120W WO2011070045A1 WO 2011070045 A1 WO2011070045 A1 WO 2011070045A1 EP 2010069120 W EP2010069120 W EP 2010069120W WO 2011070045 A1 WO2011070045 A1 WO 2011070045A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
rgm
cdr
binding
Prior art date
Application number
PCT/EP2010/069120
Other languages
English (en)
Inventor
Bernhard K. Mueller
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43806839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011070045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2010329955A priority Critical patent/AU2010329955A1/en
Priority to DK10794938.0T priority patent/DK2510001T3/en
Priority to JP2012542530A priority patent/JP5951498B2/ja
Priority to MX2012006560A priority patent/MX2012006560A/es
Priority to PL10794938T priority patent/PL2510001T3/pl
Priority to SG2012041935A priority patent/SG181563A1/en
Priority to CN2010800552755A priority patent/CN102656190A/zh
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Priority to BR112012013734A priority patent/BR112012013734A2/pt
Priority to ES10794938.0T priority patent/ES2562832T3/es
Priority to EP10794938.0A priority patent/EP2510001B1/fr
Priority to CA2780069A priority patent/CA2780069C/fr
Publication of WO2011070045A1 publication Critical patent/WO2011070045A1/fr
Priority to IL219766A priority patent/IL219766A0/en
Priority to ZA2012/04106A priority patent/ZA201204106B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des protéines de liaison à RGM A, notamment des anticorps monoclonaux, en particulier des versions humanisées et greffées aux CDR de ceux-ci, qui possèdent la capacité de se lier aux RGM A et d'empêcher la liaison des protéines RGM au récepteur des RGM A et à d'autres protéines se liant aux RGM A, et qui neutralisent par conséquent la fonction des RGM A, destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes (RNFL). La présente invention concerne également des procédés de traitement thérapeutique ou prophylactique d'un mammifère contre la dégénérescence de la RNFL.
PCT/EP2010/069120 2009-12-08 2010-12-08 Anticorps monoclonaux contre la protéine rgm a destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes WO2011070045A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2780069A CA2780069C (fr) 2009-12-08 2010-12-08 Anticorps monoclonaux contre la proteine rgm a destines a etre utilises dans le traitement de la degenerescence de la couche de fibres nerveuses retiniennes
CN2010800552755A CN102656190A (zh) 2009-12-08 2010-12-08 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
JP2012542530A JP5951498B2 (ja) 2009-12-08 2010-12-08 網膜神経線維層変性の治療に使用するためのｒｇｍａタンパク質に対するモノクローナル抗体
MX2012006560A MX2012006560A (es) 2009-12-08 2010-12-08 Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
PL10794938T PL2510001T3 (pl) 2009-12-08 2010-12-08 Monoklonalne przeciwciało przeciwko białku RGM A do zastosowania w leczeniu zwyrodnienia warstwy włókien nerwowych siatkówki (RNFL)
SG2012041935A SG181563A1 (en) 2009-12-08 2010-12-08 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
BR112012013734A BR112012013734A2 (pt) 2009-12-08 2010-12-08 anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
AU2010329955A AU2010329955A1 (en) 2009-12-08 2010-12-08 Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
DK10794938.0T DK2510001T3 (en) 2009-12-08 2010-12-08 MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
ES10794938.0T ES2562832T3 (es) 2009-12-08 2010-12-08 Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
EP10794938.0A EP2510001B1 (fr) 2009-12-08 2010-12-08 Anticorps monoclonaux contre la protéine rgm a destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes
IL219766A IL219766A0 (en) 2009-12-08 2012-05-13 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
ZA2012/04106A ZA201204106B (en) 2009-12-08 2012-06-05 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26744609P 2009-12-08 2009-12-08
US61/267,446 2009-12-08

Publications (1)

Publication Number Publication Date
WO2011070045A1 true WO2011070045A1 (fr) 2011-06-16

Family

ID=43806839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/069120 WO2011070045A1 (fr) 2009-12-08 2010-12-08 Anticorps monoclonaux contre la protéine rgm a destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes

Country Status (17)

Country Link
US (4) US9175075B2 (fr)
EP (1) EP2510001B1 (fr)
JP (5) JP5951498B2 (fr)
KR (1) KR20120118002A (fr)
CN (2) CN102656190A (fr)
AU (1) AU2010329955A1 (fr)
BR (1) BR112012013734A2 (fr)
CA (1) CA2780069C (fr)
DK (1) DK2510001T3 (fr)
EC (1) ECSP12012029A (fr)
ES (1) ES2562832T3 (fr)
IL (1) IL219766A0 (fr)
MX (1) MX2012006560A (fr)
PL (1) PL2510001T3 (fr)
SG (1) SG181563A1 (fr)
WO (1) WO2011070045A1 (fr)
ZA (1) ZA201204106B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113107A1 (fr) * 2012-02-03 2013-08-08 University Health Network Procédés pour favoriser la survie neuronale, la croissance et/ou la régénération axonale
KR20140125825A (ko) * 2012-01-27 2014-10-29 아비에 도이치란트 게엠베하 운트 콤파니 카게 신경돌기 변성과 연관된 질환의 진단 및 치료를 위한 조성물 및 방법
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2015039212A1 (fr) * 2013-09-17 2015-03-26 University Health Network (Uhn): Technology Development And Commercialization Agents dirigés contre une interaction cis rgma/néogénine ou contre les radeaux lipidiques et utilisation de ceux-ci dans des méthodes thérapeutiques
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
CN107459576A (zh) * 2011-12-14 2017-12-12 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
EP3290441A4 (fr) * 2015-04-28 2018-10-17 Mitsubishi Tanabe Pharma Corporation PROTÉINE DE LIAISON À RGMa ET SON UTILISATION
WO2019136043A1 (fr) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Protéines de fusion de co-recepteur à bras unique et utilisations associées

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
CA2855570A1 (fr) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition et methode pour le diagnostic et le traitement de troubles lies au fer
MX2017003063A (es) 2014-09-10 2017-06-14 Abbvie Deutschland Prueba de diagnostico basada en fragmento de rgma.
EP3821908A4 (fr) * 2018-07-10 2022-03-30 Mitsubishi Tanabe Pharma Corporation Méthode de prévention ou de traitement de la neuropathie périphérique ou de la douleur accompagnant une maladie dans laquelle une neuropathie périphérique ou un trouble astrocytaire est reconnu
CN116322773A (zh) * 2020-04-21 2023-06-23 马萨诸塞大学 用于治疗年龄相关性黄斑变性的方法和组合物
EP4229081A1 (fr) * 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps spécifique du domaine de liaison du récepteur du sars-cov-2 et procédés thérapeutiques

Citations (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128208A (en) 1937-02-27 1938-08-23 Du Pont Alkoxy derivatives of methacrylic acid esters and method of producing them
US4526938A (en) 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations
EP0229246A2 (fr) 1986-01-15 1987-07-22 ANT Nachrichtentechnik GmbH Méthode pour décoder des signaux numériques, décodeur Viterbi et applications
EP0239400A2 (fr) 1986-03-27 1987-09-30 Medical Research Council Anticorps recombinants et leurs procédés de production
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1990002809A1 (fr) 1988-09-02 1990-03-22 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
WO1990005144A1 (fr) 1988-11-11 1990-05-17 Medical Research Council Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990014424A1 (fr) 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Procede d'isolement de recepteurs presentant une specificite preselectionnee
WO1990014443A1 (fr) 1989-05-16 1990-11-29 Huse William D Coexpression de recepteurs heteromeres
WO1990014430A1 (fr) 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Nouveau procede d'exploitation du repertoire immunologique
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1991005548A1 (fr) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Composition a liberation entretenue pour proteines macromoleculaires
WO1991009967A1 (fr) 1989-12-21 1991-07-11 Celltech Limited Anticorps humanises
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
WO1991010737A1 (fr) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production d'anticorps utilisant des librairies de genes
WO1991017271A1 (fr) 1990-05-01 1991-11-14 Affymax Technologies N.V. Procedes de triage de banques d'adn recombine
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992002551A1 (fr) 1990-08-02 1992-02-20 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
WO1992015679A1 (fr) 1991-03-01 1992-09-17 Protein Engineering Corporation Phage de visualisation d'un determinant antigenique ameliore
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
WO1992019244A2 (fr) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procede de traitement des maladies respiratoires infectieuses
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
EP0519596A1 (fr) 1991-05-17 1992-12-23 Merck & Co. Inc. Procédé pour réduire l'immunogénécité des domaines variables d'anticorps
WO1992022324A1 (fr) 1991-06-14 1992-12-23 Xoma Corporation Fragments d'anticorps produits par des microbes et leurs conjugues
WO1993001288A1 (fr) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide utile pour trier des anticorps
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
EP0592106A1 (fr) 1992-09-09 1994-04-13 Immunogen Inc Remodelage d'anticorps des rongeurs
WO1995015982A2 (fr) 1993-12-08 1995-06-15 Genzyme Corporation Procede de generation d'anticorps specifiques
WO1995020401A1 (fr) 1994-01-31 1995-08-03 Trustees Of Boston University Banques d'anticorps polyclonaux
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1996020698A2 (fr) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
WO1997029131A1 (fr) 1996-02-09 1997-08-14 Basf Aktiengesellschaft ANTICORPS HUMAINS SE FIXANT AU FACTEUR NECROSANT DES TUMEURS DE TYPE $g(a)
WO1997032572A2 (fr) 1996-03-04 1997-09-12 The Penn State Research Foundation Materiaux et procedes permettant d'accroitre la penetration intracellulaire
US5679377A (en) 1989-11-06 1997-10-21 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
WO1997044013A1 (fr) 1996-05-24 1997-11-27 Massachusetts Institute Of Technology Particules legeres aerodynamiques pour la diffusion de medicaments dans l'appareil respiratoire
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5723323A (en) 1985-03-30 1998-03-03 Kauffman; Stuart Alan Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1998016654A1 (fr) 1996-10-11 1998-04-23 Japan Tobacco, Inc. Production de proteine multimere par procede de fusion cellulaire
US5750753A (en) 1996-01-24 1998-05-12 Chisso Corporation Method for manufacturing acryloxypropysilane
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
WO1998024893A2 (fr) 1996-12-03 1998-06-11 Abgenix, Inc. MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1998031700A1 (fr) 1997-01-21 1998-07-23 The General Hospital Corporation Selection de proteines a l'aide de fusions arn-proteine
WO1998031346A1 (fr) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1998050433A2 (fr) 1997-05-05 1998-11-12 Abgenix, Inc. Anticorps monoclonaux humains contre le recepteur du facteur de croissance epidermique
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1999015154A1 (fr) 1997-09-24 1999-04-01 Alkermes Controlled Therapeutics, Inc. Procedes de fabrication de preparations de liberation controlee a base de polymere
WO1999020253A1 (fr) 1997-10-23 1999-04-29 Bioglan Therapeutics Ab Procede d'encapsulage
WO1999025044A1 (fr) 1997-11-07 1999-05-20 Nathan Cohen Antenne a plaque a microbande dotee d'une structure fractale
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1999045031A2 (fr) 1998-03-03 1999-09-10 Abgenix, Inc. Molecules fixatrices cd147 utilisees comme agents therapeutiques
WO1999053049A1 (fr) 1998-04-15 1999-10-21 Abgenix, Inc. Production d'anticorps humains par des epitopes et formation de profils d'expression genique
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5998209A (en) 1995-04-21 1999-12-07 Abgenix, Inc. Generation of large genomic DNA deletions
WO1999066903A2 (fr) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO2000009560A2 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000037504A2 (fr) 1998-12-23 2000-06-29 Pfizer Inc. Anticorps monoclonaux humains diriges contre l'antigene ctla-4
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
WO2000056772A1 (fr) 1999-03-25 2000-09-28 Knoll Gmbh Anticorps humains se liant a l'interleukine-12 humaine et procedes de production de ces derniers
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6204023B1 (en) 1985-11-01 2001-03-20 Xoma Ltd. Modular assembly of antibody genes, antibodies prepared thereby and use
EP1176195A1 (fr) 1999-04-09 2002-01-30 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2002072636A2 (fr) 2000-12-28 2002-09-19 Altus Biologics Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
US20020137134A1 (en) 2000-06-28 2002-09-26 Gerngross Tillman U. Methods for producing modified glycoproteins
WO2003016466A2 (fr) 2001-08-17 2003-02-27 Eli Lilly And Company Anticorps anti-$g(a)$g(b)
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US20040018590A1 (en) 2000-06-28 2004-01-29 Gerngross Tillman U. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO2004078140A2 (fr) 2003-03-05 2004-09-16 Halozyme, Inc. Glycoproteine hyaluronidase soluble (shasegp), procede de fabrication et compositions pharmaceutiques contenant ladite proteine
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
WO2005100584A2 (fr) 2004-04-15 2005-10-27 Glycofi, Inc. Production de glycoproteines galactosylatees dans des eucaryotes inferieurs
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2008082651A2 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Anticorps il-1a/il-1b à double spécificité
WO2009106356A1 (fr) * 2008-02-29 2009-09-03 Abbott Gmbh & Co. Kg Anticorps monoclonaux dirigés contre la protéine rgm a et ses utilisations
US9105939B2 (en) 2008-03-10 2015-08-11 Nissan Motor Co., Ltd. Battery with battery electrode and method of manufacturing same
US9109630B2 (en) 2013-01-15 2015-08-18 Jtekt Corporation Rolling bearing unit
US9401234B2 (en) 2013-03-22 2016-07-26 Polytronics Technology Corp. Over-current protection device
US9618978B2 (en) 2013-10-03 2017-04-11 Acer Incorporated Methods for controlling a touch panel and portable computers using the same
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5635600A (en) 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0273115B1 (fr) 1986-10-22 1994-09-07 Abbott Laboratories Sels d'acridines et de phénantridines chimiluminescents
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0832981A1 (fr) * 1987-02-17 1998-04-01 Pharming B.V. Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5006309A (en) * 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) * 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
CA1340323C (fr) 1988-09-20 1999-01-19 Arnold E. Hampel Catalyseur d'arn pour le clivage de sequences specifiques d'arn
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
GB8826530D0 (en) 1988-11-12 1988-12-14 Ped Capacitors Ltd Electrical capacitors
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
GB8901334D0 (en) 1989-01-21 1989-03-15 Oakland Design Products Ltd Improvements relating to broadhead arrows
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5139400A (en) 1989-10-11 1992-08-18 Ide Russell D Progressive cavity drive train
FR2656431B1 (fr) 1989-12-22 1994-06-10 Essilor Int Procede et solution pour decontaminer une lentille souple, en particulier du type hydrophile.
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2048302A1 (fr) 1990-08-15 1992-02-16 Victoria P. Meucci Reactif de solubilisation des echantillons dans des epreuves biologiques
US5135875A (en) 1990-08-15 1992-08-04 Abbott Laboratories Protein precipitation reagent
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992005282A1 (fr) * 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Anticorps contre des complexes de recepteurs de ligand et des ligands ainsi que leur utilite dans des dosages ligands-recepteurs
GB9101134D0 (en) 1991-01-18 1991-02-27 R B S Improvements in and relating to accommodation for animals
JPH06506688A (ja) * 1991-04-10 1994-07-28 バイオサイト・ダイアグノスティックス・インコーポレイテッド クロストークインヒビターおよびその使用
EP0579767B1 (fr) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Nouveaux conjugues et dosages destines a la detection simultanee de ligands multiples
CA2069530A1 (fr) * 1991-06-03 1992-12-04 Cass J. Grandone Trousse de reactifs pour dosages immunologiques
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
ES2198823T3 (es) * 1992-03-30 2004-02-01 Abbott Laboratories Reactivos que permiten la deteccion y la cuantificacion de la tiroxina en muestras de fluido.
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
DE59309246D1 (de) 1992-07-10 1999-02-04 Horst Warneke Fertigungsstrasse zur herstellung einer stahlkassette für decken- und/oder wandkonstruktionen aus einer blechtafel
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU692239B2 (en) 1994-03-07 1998-06-04 Medarex, Inc. Bispecific molecules having clinical utilities
US5525490A (en) * 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5541109A (en) 1994-04-19 1996-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. Expression cloning of c-src SH3-domain binding proteins
ES2210306T3 (es) 1994-07-20 2004-07-01 The General Hospital Corporation Sistemas de trampa para interacciones, para detectar interacciones de proteinas.
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
ATE263781T1 (de) 1994-10-27 2004-04-15 Genentech Inc Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor
GB9425232D0 (en) 1994-12-14 1995-02-08 Secr Defence Method of authenticating watermarked paper
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0859841B1 (fr) 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
US5747262A (en) 1995-10-16 1998-05-05 The Regents Of The University Of California Neurological drug screens
US20020136725A1 (en) 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
FR2754461B1 (fr) 1996-10-16 1999-02-12 Husson Olivier Fixation demontable manuellement pour patin en ligne avec une jambiere de maintien qui commande un systeme de freinage
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
JP4060372B2 (ja) 1996-12-11 2008-03-12 ブリストル−マイヤーズ・スクイブ・カンパニー 原核生物の二ハイブリッド系
US6017517A (en) 1996-12-18 2000-01-25 The Dial Corporation Method for treating human nails
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
WO1998047343A2 (fr) 1997-04-04 1998-10-29 Biosite Diagnostics, Inc. Bibliotheques polyvalentes et polyclonales
AU7171098A (en) 1997-05-01 1998-11-24 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
IT1294449B1 (it) 1997-07-02 1999-03-24 F B C Di Giuliano Frati & C Sn Struttura calzabile sportiva e metodi per attuare la stessa in particolare per pattini monofilari e da shortracking.
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
AU750358B2 (en) 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US6464686B1 (en) * 1998-01-21 2002-10-15 Abbott Laboratories Polyurethane feeding tube and associated adaptors
WO1999051741A2 (fr) 1998-04-03 1999-10-14 Curagen Corporation Complexes de proteine lyst et proteines a interaction lyst
TWI242563B (en) 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
EP1095154A2 (fr) 1998-07-10 2001-05-02 Curagen Corporation Interaction de precurseur de la proteine beta-amyloide humaine (beta-app) et de proteine humaine du type lon-protease (hslon)
IL128017A0 (en) 1998-07-22 1999-11-30 Technion Res & Dev Foundation Method for detecting protein-protein interactions and a kit therefor
EP1109931A4 (fr) 1998-09-03 2004-12-15 Univ Loma Linda PROCEDE D'ETUDE D'INTERACTIONS DE PROTEINES $i(IN VIVO)
WO2000017221A1 (fr) 1998-09-24 2000-03-30 Duke University Procede de mesure des interactions proteine-proteine dans des cellules vivantes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1135498T3 (da) 1998-11-18 2008-05-26 Genentech Inc Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
US6231768B1 (en) 1999-01-19 2001-05-15 Nalco Chemical Company Rheology modification of settled solids in mineral processing
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP2003518364A (ja) 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
EP1396543A3 (fr) 1999-07-08 2004-03-31 Research Association for Biotechnology Amorces pour la synthèse de cADN de pleine longueur et leur utilisation
EP2829609A1 (fr) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Anticorps CTLA-4 humains et leurs utilisations
GB9930001D0 (en) * 1999-12-21 2000-02-09 Phaeton Research Ltd An ingestible device
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
AU2001237958A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. 22 human secreted proteins
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
AU2001238677A1 (en) 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
US6800455B2 (en) 2000-03-31 2004-10-05 Scios Inc. Secreted factors
ES2528794T3 (es) * 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
CA2407956A1 (fr) 2000-05-03 2001-11-08 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE60137421D1 (de) 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
KR101054732B1 (ko) 2000-07-18 2011-08-05 더 유나이티드 스테이츠 오브 아메리카 애즈 리프리젠티드 바이 더 세크레터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 생물학적 데이터의 숨겨진 패턴에 근거한 생물학적 상태의 식별 방법
ES2296829T3 (es) * 2000-11-06 2008-05-01 Cancer Research Technology Limited Imaginologia, diagnostico y tratamiento de la enfermedad.
ES2390425T3 (es) * 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6890763B2 (en) 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
US20100036502A1 (en) * 2008-08-07 2010-02-11 Exogenesis Corporation Medical device for bone implant and method for producing such device
EP1270044A3 (fr) * 2001-06-18 2003-03-12 Pfizer Limited Biomarqueurs de la cicatrisation de blessure
JP2005512512A (ja) 2001-07-05 2005-05-12 インサイト・ゲノミックス・インコーポレイテッド 分泌タンパク質
WO2003020894A2 (fr) * 2001-08-31 2003-03-13 Joslin Diabetes Center, Inc. Facteur de transcription lie a l'insuline et utilisations de celui-ci
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2467597A1 (fr) 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
US8435529B2 (en) * 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
CA2480388A1 (fr) 2002-03-27 2003-10-02 Theratechnologies Inc. Procedes et composes pour la prevention et le traitement de la pression intraoculaire elevee et etats connexes
US7319138B2 (en) * 2002-04-18 2008-01-15 The General Hospital Corporation Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
WO2003095978A2 (fr) 2002-05-09 2003-11-20 Surromed, Inc. Procedes d'alignement temporel de donnees obtenues par chromatographie liquide ou par spectrometrie de masse
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1535065A4 (fr) * 2002-06-11 2007-07-11 Burnham Inst Synergie neuroprotectrice de l'erythropoietine et du facteur de croissance semblable a l'insuline
US7771952B2 (en) * 2002-06-26 2010-08-10 Abott Laboratories Modulators and modulation of the interaction between RGM and Neogenin
EP1380644A1 (fr) 2002-07-08 2004-01-14 Kylix B.V. Utilisation de gènes cible spécifiques de TCF pour identifier des medicaments pour le traitement du cancer, en particulier le cancer colorectal, dans lequel TCF/beta-catenin/WNT signalisation joue un rôle central
US20040018577A1 (en) * 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
AU2003298799A1 (en) * 2002-12-02 2004-06-23 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
AU2003299581A1 (en) * 2002-12-02 2004-06-23 Abgenix, Inc. Antibodies against drugs of abuse
EP1440981A3 (fr) 2003-01-21 2005-11-23 Research Association for Biotechnology ADN complementaire humaine de pleine longueur
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
CA2522680A1 (fr) * 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Gene d'hemochromatose juvenile (hfe2a), produits d'expression et leurs utilisations
AU2004234191A1 (en) 2003-04-30 2004-11-11 University Of Zurich Methods for treating cancer using an immunotoxin
EA008253B1 (ru) 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
PL380274A1 (pl) 2003-08-07 2007-01-22 Biogen Idec Ma Inc. Antagoniści receptora Nogo
ATE420660T1 (de) 2003-08-08 2009-01-15 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
US20060003391A1 (en) 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) * 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
AU2004290085A1 (en) * 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
WO2005061544A2 (fr) 2003-12-22 2005-07-07 Glaxo Group Limited Immunoglobulines
WO2005061554A1 (fr) 2003-12-24 2005-07-07 Idemitsu Kosan Co., Ltd. Procede et dispositif de fabrication de polyolefines
US20110171126A1 (en) 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
CA2559069A1 (fr) 2004-03-11 2005-09-22 Bioclues, Inc. Promoteur de regeneration d'axones
US20060063208A1 (en) * 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
WO2006021955A2 (fr) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Utilisation d'anticorps monoclonaux bat pour l'immunotherapie
WO2006026222A2 (fr) 2004-08-25 2006-03-09 Genentech, Inc. Disruptions geniques; compositions et methodes y relatives
EP2194144B1 (fr) * 2004-11-16 2015-01-07 Trustees of Boston University Anticorps anti-double récepteur pour l'Endothéline-1 et l'Angiotensine II (DEAR) pour l'inhibition de l'angiogenèse associée à une maladie ou de l'angiogenèse pathologique
EP2322206A3 (fr) 2004-11-22 2013-06-05 Centre National de la Recherche Scientifique Nétrine 1 mutée, ses fragments et leur utilisation comme médicaments
PE20061401A1 (es) 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
EP1677113A1 (fr) 2004-12-29 2006-07-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Procédé d'identification des interactions protéine-protéine dans des réseaux de protéines associés aux maladies
ES2547866T3 (es) 2005-02-16 2015-10-09 The General Hospital Corporation Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
AU2006222193B2 (en) 2005-03-05 2011-11-17 AbbVie Deutschland GmbH & Co. KG Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
WO2007086915A2 (fr) 2005-05-12 2007-08-02 Applied Genomics, Inc. Reactifs et leurs procedes d’utilisation lors du diagnostic, de la classification et de la therapie de cancers
EP1907845A4 (fr) 2005-05-25 2009-03-04 Expression Pathology Inc Diagnostic de maladies et d'états pathologiques par l'analyse d'échantillons biologiques traités par voie histopathologique à l'aide de préparations tissulaires liquides
MX2008000253A (es) * 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US20100168393A1 (en) 2005-10-11 2010-07-01 Big Glucose Ltd. Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides
US20070155687A1 (en) 2005-10-14 2007-07-05 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20080004255A1 (en) * 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
US8865763B2 (en) * 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
AU2006339538A1 (en) 2005-11-08 2007-09-13 Euclid Diagnostics Llc Materials and methods for assaying for methylation of CpG islands associated with genes in the evaluation of cancer
WO2007058671A1 (fr) 2005-11-21 2007-05-24 West Michael D Nouvelles utilisations de cellules a motifs prenatals de l'expression genique
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
PL2596807T3 (pl) 2006-03-08 2016-06-30 Archemix Llc Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych
WO2007106507A2 (fr) 2006-03-14 2007-09-20 Petrie Howard T Détection de l'expression génique dans un échantillon ou un tissu mixte
EP1865071A1 (fr) 2006-06-09 2007-12-12 Rheinische Friedrich-Wilhelms-Universität Bonn Méthode de diagnostic précoce de la rétinopathie diabétique proliférative
US7883855B2 (en) * 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
EP2052089A4 (fr) 2006-07-28 2010-05-05 Chundsell Medicals Ab Marqueurs de cellules souches embryonnaires destinés à établir un diagnostic ou un pronostic de cancer
WO2008038599A1 (fr) 2006-09-25 2008-04-03 National University Corporation Chiba University Promoteur de régénération axonale
US8066154B2 (en) * 2006-10-02 2011-11-29 Norman Schmidt Device for controlled metering of semi solid food products
CA2607490C (fr) * 2006-10-18 2018-04-10 Norman G. Schmidt Dispositif permettant l'acces pour le nettoyage dans les machines de dosage d'aliments semi-solides
EP2097450A2 (fr) * 2006-11-10 2009-09-09 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
CA2670368C (fr) 2006-11-21 2018-05-29 Abbott Laboratories Neutralisation d'anticorps monoclonaux contre le recepteur nogo-66 (ngr) et leurs utilisations
EP2104734A2 (fr) 2006-12-08 2009-09-30 Asuragen, INC. Gènes et voies génétiques régulés par le mir-20 en tant que cibles en vue d'une intervention thérapeutique
AU2007333110A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miRNA regulated genes and pathways as targets for therapeutic intervention
KR101343916B1 (ko) 2006-12-21 2013-12-20 삼성전자주식회사 폐암의 림프절 미세전이 진단용 마커, 상기 마커에 대한프라이머를 포함하는 키트, 상기 마커 또는 상기 마커에대한 항체를 포함하는 마이크로어레이, 및 폐암의 림프절미세전이 여부를 진단하는 방법
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP1947114A1 (fr) 2007-01-19 2008-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nétrine 4 mutée, ses fragments et leur utilisation comme médicaments
CN109456410B (zh) * 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US7906293B2 (en) 2007-04-09 2011-03-15 Abbott Laboratories Acridinium phenyl esters useful in the analysis of biological
WO2008127735A1 (fr) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Conjugués d'anticorps il3ralpha et leurs utilisations
WO2009002386A2 (fr) 2007-05-24 2008-12-31 The Regents Of The University Of Californina Effet biologique dependant de la taille d'une nanoparticule
US8070827B2 (en) * 2007-07-03 2011-12-06 Histogenics Corporation Method for use of a double-structured tissue implant for treatment of tissue defects
US20090054984A1 (en) * 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
WO2009026392A1 (fr) 2007-08-20 2009-02-26 Histogenics Corporation Procédé pour améliorer la différenciation des cellules souches mésenchymateuses à l'aide d'un implant tissulaire à double structure
EP2033971A1 (fr) 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Domaines de protéines recombinantes des protéines morphogénétiques osseuses (BMP) de la famille des Repulsive Guidance Molecule (RGM) et leurs fragments fonctionnels ainsi que leur utilisation
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
JP5674469B2 (ja) 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
EP2220122A2 (fr) 2007-11-13 2010-08-25 Teva Biopharmaceuticals USA, Inc. Anticorps humanises contre tl1a
GB2456390A (en) 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
EP2581457A3 (fr) 2008-01-17 2013-07-17 Suregene LLC Marqueurs génétiques de maladie mentale
WO2009094592A2 (fr) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Base génétique de la maladie d'alzheimer et diagnostic et traitement de cette dernière
BRPI0907718A2 (pt) * 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
WO2009105624A2 (fr) 2008-02-21 2009-08-27 Massachusetts Institute Of Technology Transfert simultané de récepteurs et/ou de co-récepteurs pour la stabilité et l'activité de facteurs de croissance
CA2717169A1 (fr) 2008-03-01 2009-09-17 Abraxis Bioscience, Llc Traitement, diagnostic et procede pour decouvrir un antagoniste a l'aide d'arnmi specifique de sparc
DE102008014880A1 (de) 2008-03-12 2009-09-17 Eberhard-Karls-Universität Tübingen Antientzündliches Polypeptid
US8314213B2 (en) * 2008-04-18 2012-11-20 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2009140383A2 (fr) 2008-05-13 2009-11-19 Archemix Corp. Aptamères qui se lient à la p-sélectine et leur utilisation en tant que produits thérapeutiques de maladie de coagulation, thrombotique, inflammatoire et métastasique
CA2726087A1 (fr) 2008-06-03 2009-12-10 Tariq Ghayur Immunoglobulines a deux domaines variables et leurs utilisations
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
WO2010006184A2 (fr) 2008-07-11 2010-01-14 Emory University Inhibiteurs à petites molécules de hif et d'angiogenèse
WO2010006189A2 (fr) 2008-07-11 2010-01-14 Emory University Inhibiteurs de petite molécule de l’hif et de l'angiogenèse
US20100184033A1 (en) 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
WO2010007144A2 (fr) 2008-07-18 2010-01-21 Centre National De La Recherche Scientifique Nouvelles protéines de nétrine 4 mutées, fragments de celles-ci et leurs utilisations en tant que médicaments
WO2010021696A1 (fr) 2008-08-18 2010-02-25 The Board Of Trustees Of The Leland Stanford Junior University Procédés et compositions pour déterminer un phénotype tolérant à une greffe chez un sujet
NZ591544A (en) * 2008-09-30 2013-01-25 Abbott Lab Improved method of rna display
TW201028432A (en) * 2008-09-30 2010-08-01 Abbott Lab Improved antibody libraries
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR101039751B1 (ko) 2008-10-16 2011-06-09 한국생명공학연구원 Ｔｍｐｒｓｓ４―특이적인 인간항체
WO2010059861A1 (fr) 2008-11-20 2010-05-27 University Of Southern California Compositions et procédés de modulation de la pousse des cheveux
WO2010062914A1 (fr) 2008-11-26 2010-06-03 The Johns Hopkins University Procédés d'identification d'un risque de cancer
ES2602459T3 (es) 2008-12-26 2017-02-21 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-CD4
WO2010088688A2 (fr) 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnostic de cancer du sein in situ et invasif
US20100254979A1 (en) 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
AU2010225456B2 (en) 2009-03-18 2016-03-17 Carina Biotech Pty Ltd Biomarkers and uses thereof
US20110020221A1 (en) * 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
RU2011148913A (ru) 2009-05-01 2013-06-10 Эбботт Лэборетриз Иммуноглобулин с двумя вариабельными доменами и его применение
EP2448972A4 (fr) 2009-06-30 2012-11-28 Res Dev Foundation Polypeptides fc d'immunoglobuline
EP2483690A1 (fr) 2009-09-29 2012-08-08 Protagen AG Séquences de marqueurs pour affections cancéreuses du pancréas, carcinome pancréatique et leur utilisation
WO2011039734A2 (fr) 2009-10-02 2011-04-07 Enzo Medico Utilisation de gènes impliqués dans l'indépendance d'ancrage pour l'optimisation du diagnostic et du traitement du cancer humain
IN2012DN02604A (fr) * 2009-10-23 2015-09-04 Millennium Pharm Inc
EP2507397A4 (fr) 2009-12-01 2013-05-01 Compendia Bioscience Inc Classification des cancers
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
KR20120120193A (ko) 2009-12-09 2012-11-01 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
CA2794499A1 (fr) 2010-04-01 2011-10-06 Immumomedics, Inc. Utilisation d'anticorps pour reduire le nombre de cellules contenant des antigenes et de cellules dendritiques
MY176695A (en) * 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
MX2017003063A (es) * 2014-09-10 2017-06-14 Abbvie Deutschland Prueba de diagnostico basada en fragmento de rgma.

Patent Citations (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128208A (en) 1937-02-27 1938-08-23 Du Pont Alkoxy derivatives of methacrylic acid esters and method of producing them
US4526938A (en) 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5976862A (en) 1985-03-30 1999-11-02 Ixsys Corporation Process for obtaining DNA, RNA, peptides, polypeptides, or proteins, by recombinant DNA technique
US5824514A (en) 1985-03-30 1998-10-20 Stuart A. Kauffman Process for the production of expression vectors comprising at least one stochastic sequence of polynucleotides
US5817483A (en) 1985-03-30 1998-10-06 Stuart Kauffman Process for the production of stochastically-generated peptides,polypeptides or proteins having a predetermined property
US5814476A (en) 1985-03-30 1998-09-29 Stuart Kauffman Process for the production of stochastically-generated transcription or translation products
US5723323A (en) 1985-03-30 1998-03-03 Kauffman; Stuart Alan Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US6204023B1 (en) 1985-11-01 2001-03-20 Xoma Ltd. Modular assembly of antibody genes, antibodies prepared thereby and use
EP0229246A2 (fr) 1986-01-15 1987-07-22 ANT Nachrichtentechnik GmbH Méthode pour décoder des signaux numériques, décodeur Viterbi et applications
EP0239400A2 (fr) 1986-03-27 1987-09-30 Medical Research Council Anticorps recombinants et leurs procédés de production
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5571698A (en) 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
WO1990002809A1 (fr) 1988-09-02 1990-03-22 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5403484A (en) 1988-09-02 1995-04-04 Protein Engineering Corporation Viruses expressing chimeric binding proteins
WO1990005144A1 (fr) 1988-11-11 1990-05-17 Medical Research Council Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
WO1990014430A1 (fr) 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Nouveau procede d'exploitation du repertoire immunologique
WO1990014443A1 (fr) 1989-05-16 1990-11-29 Huse William D Coexpression de recepteurs heteromeres
WO1990014424A1 (fr) 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Procede d'isolement de recepteurs presentant une specificite preselectionnee
WO1991005548A1 (fr) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Composition a liberation entretenue pour proteines macromoleculaires
US5679377A (en) 1989-11-06 1997-10-21 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
WO1991009967A1 (fr) 1989-12-21 1991-07-11 Celltech Limited Anticorps humanises
WO1991010737A1 (fr) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production d'anticorps utilisant des librairies de genes
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6114598A (en) 1990-01-12 2000-09-05 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991017271A1 (fr) 1990-05-01 1991-11-14 Affymax Technologies N.V. Procedes de triage de banques d'adn recombine
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5580717A (en) 1990-05-01 1996-12-03 Affymax Technologies N.V. Recombinant library screening methods
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
US5969108A (en) 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
WO1992002551A1 (fr) 1990-08-02 1992-02-20 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
US5627052A (en) 1990-08-02 1997-05-06 B.R. Centre, Ltd. Methods for the production of proteins with a desired function
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5821047A (en) 1990-12-03 1998-10-13 Genentech, Inc. Monovalent phage display
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
WO1992015679A1 (fr) 1991-03-01 1992-09-17 Protein Engineering Corporation Phage de visualisation d'un determinant antigenique ameliore
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
WO1992019244A2 (fr) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procede de traitement des maladies respiratoires infectieuses
EP0519596A1 (fr) 1991-05-17 1992-12-23 Merck & Co. Inc. Procédé pour réduire l'immunogénécité des domaines variables d'anticorps
WO1992022324A1 (fr) 1991-06-14 1992-12-23 Xoma Corporation Fragments d'anticorps produits par des microbes et leurs conjugues
WO1993001288A1 (fr) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide utile pour trier des anticorps
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6350861B1 (en) 1992-03-09 2002-02-26 Protein Design Labs, Inc. Antibodies with increased binding affinity
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
EP0592106A1 (fr) 1992-09-09 1994-04-13 Immunogen Inc Remodelage d'anticorps des rongeurs
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1995015982A2 (fr) 1993-12-08 1995-06-15 Genzyme Corporation Procede de generation d'anticorps specifiques
WO1995020401A1 (fr) 1994-01-31 1995-08-03 Trustees Of Boston University Banques d'anticorps polyclonaux
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
WO1996020698A2 (fr) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5998209A (en) 1995-04-21 1999-12-07 Abgenix, Inc. Generation of large genomic DNA deletions
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5750753A (en) 1996-01-24 1998-05-12 Chisso Corporation Method for manufacturing acryloxypropysilane
WO1997029131A1 (fr) 1996-02-09 1997-08-14 Basf Aktiengesellschaft ANTICORPS HUMAINS SE FIXANT AU FACTEUR NECROSANT DES TUMEURS DE TYPE $g(a)
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
WO1997032572A2 (fr) 1996-03-04 1997-09-12 The Penn State Research Foundation Materiaux et procedes permettant d'accroitre la penetration intracellulaire
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5985615A (en) 1996-03-20 1999-11-16 Abgenix, Inc. Directed switch-mediated DNA recombination
WO1997044013A1 (fr) 1996-05-24 1997-11-27 Massachusetts Institute Of Technology Particules legeres aerodynamiques pour la diffusion de medicaments dans l'appareil respiratoire
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1998016654A1 (fr) 1996-10-11 1998-04-23 Japan Tobacco, Inc. Production de proteine multimere par procede de fusion cellulaire
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (fr) 1996-12-03 1998-06-11 Abgenix, Inc. MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1998031346A1 (fr) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
WO1998031700A1 (fr) 1997-01-21 1998-07-23 The General Hospital Corporation Selection de proteines a l'aide de fusions arn-proteine
WO1998050433A2 (fr) 1997-05-05 1998-11-12 Abgenix, Inc. Anticorps monoclonaux humains contre le recepteur du facteur de croissance epidermique
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999015154A1 (fr) 1997-09-24 1999-04-01 Alkermes Controlled Therapeutics, Inc. Procedes de fabrication de preparations de liberation controlee a base de polymere
WO1999020253A1 (fr) 1997-10-23 1999-04-29 Bioglan Therapeutics Ab Procede d'encapsulage
WO1999025044A1 (fr) 1997-11-07 1999-05-20 Nathan Cohen Antenne a plaque a microbande dotee d'une structure fractale
WO1999045031A2 (fr) 1998-03-03 1999-09-10 Abgenix, Inc. Molecules fixatrices cd147 utilisees comme agents therapeutiques
WO1999053049A1 (fr) 1998-04-15 1999-10-21 Abgenix, Inc. Production d'anticorps humains par des epitopes et formation de profils d'expression genique
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
WO1999066903A2 (fr) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
WO2000009560A2 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
WO2000037504A2 (fr) 1998-12-23 2000-06-29 Pfizer Inc. Anticorps monoclonaux humains diriges contre l'antigene ctla-4
WO2000056772A1 (fr) 1999-03-25 2000-09-28 Knoll Gmbh Anticorps humains se liant a l'interleukine-12 humaine et procedes de production de ces derniers
EP1176195A1 (fr) 1999-04-09 2002-01-30 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US20020137134A1 (en) 2000-06-28 2002-09-26 Gerngross Tillman U. Methods for producing modified glycoproteins
US20040018590A1 (en) 2000-06-28 2004-01-29 Gerngross Tillman U. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
WO2002072636A2 (fr) 2000-12-28 2002-09-19 Altus Biologics Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
WO2003016466A2 (fr) 2001-08-17 2003-02-27 Eli Lilly And Company Anticorps anti-$g(a)$g(b)
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
WO2004078140A2 (fr) 2003-03-05 2004-09-16 Halozyme, Inc. Glycoproteine hyaluronidase soluble (shasegp), procede de fabrication et compositions pharmaceutiques contenant ladite proteine
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
WO2005100584A2 (fr) 2004-04-15 2005-10-27 Glycofi, Inc. Production de glycoproteines galactosylatees dans des eucaryotes inferieurs
WO2008082651A2 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Anticorps il-1a/il-1b à double spécificité
WO2009106356A1 (fr) * 2008-02-29 2009-09-03 Abbott Gmbh & Co. Kg Anticorps monoclonaux dirigés contre la protéine rgm a et ses utilisations
US9105939B2 (en) 2008-03-10 2015-08-11 Nissan Motor Co., Ltd. Battery with battery electrode and method of manufacturing same
US9109630B2 (en) 2013-01-15 2015-08-18 Jtekt Corporation Rolling bearing unit
US9401234B2 (en) 2013-03-22 2016-07-26 Polytronics Technology Corp. Over-current protection device
US9618978B2 (en) 2013-10-03 2017-04-11 Acer Incorporated Methods for controlling a touch panel and portable computers using the same
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Non-Patent Citations (167)

* Cited by examiner, † Cited by third party
Title
"Antibody Engineering", 2001, SPRINGER-VERLAG, pages: 790
"Current Protocols in Molecular Biology", 1993, JOHN WILEY & SONS
"Drug Product Design and Performance", 1984, WILEY, article "Controlled Drug Bioavailability"
"Medical Applications of Controlled Release", 1974, CRC PRES.
"Remington's Pharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms", 1995, MACK PUB. CO.
"Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC.
AMES ET AL., J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186
ARA ET AL., J. NEUROSCI.RES., vol. 86, 2008, pages 125 - 35
AZZAZY H.; HIGHSMITH W.E., CLIN. BIOCHEM., vol. 35, 2002, pages 425 - 445
BABCOCK, J.S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7843 - 7848
BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 42 6
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRAISTED ET AL., J. NEUROSCI., vol. 20, 2000, pages 5792 - 801
BRINKMAN ET AL., J. IMMUNOL. METHODS, vol. 182, 1995, pages 41 - 50
BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507
BURTON ET AL., ADVANCES IN IMMUNOLOGY, vol. 57, 1994, pages 191 - 280
CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, 1992, pages 4285
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 907
CHOTHIA ET AL., J. MOL. BIOL., vol. 227, 1992, pages 799
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CLEEK ET AL.: "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application", PRO. INT'L. SYMP. CONTROL. REL. BIOACT. MATER., vol. 24, 1997, pages 853 - 854
CO, M.S. ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 1361 - 1367
COSTELLO ET AL., ANN. NEUROL., vol. 59, 2006, pages 963 - 969
DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351
FANGER ET AL., IMMUNOL METHODS, vol. 4, 1994, pages 72 - 81
FOOTE; WINTER, J. MOL. BIOL., vol. 224, 1992, pages 487 - 499
FRISEN, L.; HOYL, W.F., ARCH. OPTHALMOL., vol. 92, 1974, pages 91 - 97
FROHMAN ET AL., ARCH. NEUROL., vol. 65, 2008, pages 26 - 35
FROHMAN ET AL., ARCH. NEUROL., vol. 65, no. 1, 2008, pages 26 - 35
FROHMAN ET AL., NATURE CLINICAL PRACTICE NEUROLOGY, vol. 4, no. 12, 2008, pages 664 - 675
FUCHS ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1370 - 1372
GARRAD ET AL., BIOLTECHNOLOGY, vol. 2, 1991, pages 1373 - 1377
GAVILONDO J.V.; LARRICK J.W., BIOTECHNIQUES, vol. 29, 2002, pages 128 - 145
GHEITH MOATAZ E ET AL: "Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%).", CLINICAL OPHTHALMOLOGY (AUCKLAND, N.Z.) MAR 2008 LNKD- PUBMED:19668385, vol. 2, no. 1, March 2008 (2008-03-01), pages 15 - 20, XP002632176, ISSN: 1177-5467 *
GIEGE, R.; DUCRUIX, A. BARRETT: "Crystallization of Nucleic Acids and Proteins, a Practical Approach", vol. 20, 1999, OXFORD UNIVERSITY PRESS, pages: 1 - 16
GIEGE, R.; DUCRUIX, A. BARRETT: "Crystallization of Nucleic Acids and Proteins, a Practical Approach, 2nd ea., pp. 20", 1999, OXFORD UNIVERSITY PRESS, pages: 1 - 16
GILLIES ET AL., J. IMMUNOL. METHODS, vol. 125, 1989, pages 191 - 202
GOLDSPIEL ET AL., CLINICAL PHARMACY, vol. 12, 1993, pages 488 - 505
GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138
GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580
GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21
GREEN; JAKOBOVITS, J. EXP. MED., vol. 188, 1998, pages 483 - 495
GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734
HALL; MILLER, J. NEUROSCI. RES., vol. 76, 2004, pages 1 - 8
HAMMERLING ET AL.: "Monoclonal Antibodies and T-Cell Hybridomas", 1981, ELSEVIER, pages: 563 - 681
HARLOW ET AL.: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
HATA ET AL., J. CELL BIOL., vol. 173, 2006, pages 47 - 58
HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896
HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85
HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137
HOOGENBOOM H.; CHAMES P., IMMUNOLOGY TODAY, vol. 21, 2000, pages 371 - 378
HOOGENBOOM H.R., TIB TECH., vol. 15, 1997, pages 62 - 70
HORSLEY MICHAEL B ET AL: "Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.", AMERICAN JOURNAL OF OPHTHALMOLOGY OCT 2010 LNKD- PUBMED:20643396, vol. 150, no. 4, October 2010 (2010-10-01), pages 558 - 561.E1, XP002632182, ISSN: 1879-1891 *
HOWARD ET AL., J. NEUROSURG., vol. 7 1, 1989, pages 105
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
HUSTON ET AL., METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 46 - 88
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
J6NSSON, U. ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26
J6NSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627
JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277
JOHNSSON, B. ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages 125 - 131
JOLIOT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 1864 - 1868
JONES ET AL., NATURE, vol. 321, 1986, pages 522
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KABAT ET AL., ANN. NYACAD, SCI., vol. 190, 1971, pages 382 - 391
KABAT ET AL., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 1983
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, NATIONAL INSTITUTES OF HEALTH
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NIH PUBLICATION NO. 91-3242
KABAT, E.A. ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NIH PUBLICATION NO. 91-3242
KALLENBACH K.; FREDERIKSEN J., EUR. J. NEUROL., vol. 14, 2007, pages 841 - 849
KANAMORI. A. ET AL., OPHTHALMOLOGICA, vol. 217, 2003, pages 273 - 278
KEINO-MASU ET AL., CELL, vol. 87, no. 2, 1996, pages 175 - 85
KELLERMANN S-A.; GREEN L.L., CURRENT OPINION IN BIOTECHNOLOGY, vol. 13, 2002, pages 593 - 597
KETTLEBOROUGH ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958
KIPRIYANOV ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101
KIPRIYANOV ET AL., MOLECULAR IMMUNOLOGY, vol. 31, 1994, pages 1047 - 1058
KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101
KIPRIYANOV, S.M. ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 1047 - 1058
KNOELL ET AL., NATURE PROTOCOLS, vol. 2, 2007, pages 1216 - 1224
KOEBERLE P D ET AL: "The repulsive guidance molecule, RGMa, promotes retinal ganglion cell survival in vitro and in vivo.", NEUROSCIENCE 11 AUG 2010 LNKD- PUBMED:20457227, vol. 169, no. 1, 11 August 2010 (2010-08-11), pages 495 - 504, XP002632181, ISSN: 1873-7544 *
KOHLER, G.; MILSTEIN, NATURE, vol. 256, 1975, pages 495
KOHLER; MILSTEIN: "hybridoma methodology", NATURE, vol. 256, 1975, pages 495 - 497
KRIEGLER: "Gene Transfer and Expression, A Laboratory Manual", 1990, STOCKTON PRESS
KYOTO ET AL., BRAIN RES., vol. 1186, 2007, pages 74 - 86
LAI ET AL., NEUROREPORT, vol. 8, 1997, pages 2691 - 94
LAM ET AL.: "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery", PROC. INT'L. SYMP. CONTROL REL. BIOACT. MATER., vol. 24, 1997, pages 759 - 760
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
LAURA MARIE CAMUS ET AL: "Molecular Evolution of Hemojuvelin and the Repulsive Guidance Molecule Family", JOURNAL OF MOLECULAR EVOLUTION, SPRINGER-VERLAG, NE, vol. 65, no. 1, 25 June 2007 (2007-06-25), pages 68 - 81, XP019538398, ISSN: 1432-1432, DOI: DOI:10.1007/S00239-006-0241-5 *
LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190
LINGOR ET AL., J. NEUROCHEM., vol. 103, 2007, pages 181 - 189
LITTLE M. ET AL., IMMUNOLOGY TODAY, vol. 21, 2000, pages 364 - 370
LUND ET AL., J. IMMUNOL., vol. 147, 1991, pages 2657
MACCALLUM, J MOL BIOL, vol. 262, no. 5, 1996, pages 732 - 45
MARCHALONIS ET AL., ADV EXP MED BIOL., vol. 484, 2001, pages 13 - 30
MARTINEZ ET AL., BRAIN RES., vol. 894, 2001, pages 1 - 11
MATSUNAGA EIJI ET AL: "Repulsive guidance molecule/neogenin: a novel ligand-receptor system playing multiple roles in neural development.", DEVELOPMENT, GROWTH & DIFFERENTIATION DEC 2004 LNKD- PUBMED:15610137, vol. 46, no. 6, December 2004 (2004-12-01), pages 481 - 486, XP002632180, ISSN: 0012-1592 *
MATSUURA ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 360, 2007, pages 868 - 73
MCCAFFERTY ET AL., 30 NATURE, vol. 34, no. 8, 1990, pages 552 - 554
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554
MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156
MONNIER ET AL., NATURE, vol. 419, 2002, pages 392 - 395
MONNIER PHILIPPE P ET AL: "RGM is a repulsive guidance molecule for retinal axons.", NATURE 26 SEP 2002 LNKD- PUBMED:12353034, vol. 419, no. 6905, 26 September 2002 (2002-09-26), pages 392 - 395, XP002632179, ISSN: 0028-0836 *
MORGAN; ANDERSON, ANN. REV. BIOCHEM., vol. 62, 1993, pages 191 - 217
MORRIS RW ET AL., OPTOMETRY, vol. 80, 2009, pages 83 - 100
MORRISON ET AL., PROC. NATL. ACAD. SCI., vol. 81, 1984, pages 851 - 855
MORRISON, SCIENCE, vol. 229, 1985, pages 1202
MUELLER ET AL., PHILOS. TRANS. R. SOC. LOND. B BIOL. SCI., vol. 361, 2006, pages 1513 - 29
MUELLER: "Molecular Basis of Axon Growth and Nerve Pattern Formation", 1997, JAPAN SCIENTIFIC SOCIETIES PRESS, pages: 215 - 229
MULLIGAN, SCIENCE, vol. 260, 1993, pages 926 - 932
MULLINAX ET AL., BIOTECHNIQUES, vol. 12, no. 6, 1992, pages 864 - 869
NEUBERGER ET AL., NATURE, vol. 312, 1984, pages 604 - 608
NING ET AL.: "Intratumoral Radioimmunotheraphy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel", RADIOTHERAPY &ONCOLOGY, vol. 39, 1996, pages 179 - 189
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214
PADLAN, FASEB J., vol. 9, 1995, pages 133 - 139
PADLAN, MOLECULAR IMMUNOLOGY, vol. 28, no. 4/5, 1991, pages 489 - 498
PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18
POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123
PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623
R. JEFFERIS, BIOTECHNOL. PROG., vol. 21, 2005, pages 11 - 16
R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621
RAJAGOPALAN ET AL., NAT CELL BIOL., vol. 6, no. 8, 2004, pages 756 - 62
RAJAGOPALAN SRIKANTH ET AL: "Neogenin mediates the action of repulsive guidance molecule", NATURE CELL BIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 6, no. 8, 1 August 2004 (2004-08-01), pages 756 - 762, XP002424999, ISSN: 1465-7392, DOI: DOI:10.1038/NCB1156 *
RANGER; PEPPAS, J., MACROMOL. SCI. REV. MACROMOL. CHEM., vol. 23, 1983, pages 61
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323
ROBERTS, R.W.; SZOSTAK, J.W., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 12297 - 12302
ROGUSKA ET AL., PNAS, vol. 91, 1994, pages 969 - 973
SAKATA LM ET AL., CLIN. EXPERIMENT OPHTALMOL., vol. 37, 2009, pages 90 - 99
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SAUDEK ET AL., N. ENGL. J. MED., vol. 321, 1989, pages 574
SAWAI ET AL., AJRI, vol. 34, 1995, pages 26 - 34
SCHAFFAR ET AL., J. NEUROCHEMISTRY, vol. 107, 2008, pages 418 - 431
SCHNICHELS SVEN ET AL: "Gene expression of the repulsive guidance molecules/neogenin in the developing and mature mouse visual system: C57BL/6J vs. the glaucoma model DBA/2J.", GENE EXPRESSION PATTERNS : GEP DEC 2007 LNKD- PUBMED:17942375, vol. 8, no. 1, December 2007 (2007-12-01), pages 1 - 11, XP002632178, ISSN: 1567-133X *
SCHWAB ET AL., ARCH. NEUROL., vol. 62, 2005, pages 1561 - 8
SCHWAB ET AL., EUR. J. NEUROSCI., vol. 21, 2005, pages 1569 - 76
SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 20
SETOGUCHI ET AL., EXP. NEUROL., vol. 189, 2004, pages 33 - 44
SHAPIRO ET AL., CRIT. REV. IMMUNOL., vol. 22, no. 3, 2002, pages 183 - 200
SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740
SHU ET AL., PNAS, vol. 90, 1993, pages 7995 - 7999
SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296
SKERRA ET AL., SCIENCE, vol. 240, 1988, pages 1038 - 1040
SONG ET AL.: "Antibody Mediated Lung Targeting of Long- Circulating Emulsions", PDA JOURNAL OF PHARMACEUTICAL SCIENCE &TECHNOLOGY, vol. 50, 1995, pages 372 - 397
STAHL ET AL., NEURON, vol. 5, 1990, pages 735 - 43
STUDNICKA ET AL., PROTEIN ENGINEERING, vol. 7, no. 6, 1994, pages 805 - 814
TAKEDA ET AL., NATURE, vol. 314, 1985, pages 452 - 454
TANTRI A. ET AL., SURV. OPHTALMOL., vol. 49, pages 214 - 230
TASSEW NARDOS G ET AL: "Intraretinal RGMa is involved in retino-tectal mapping.", MOLECULAR AND CELLULAR NEUROSCIENCES APR 2008 LNKD- PUBMED:18280178, vol. 37, no. 4, April 2008 (2008-04-01), pages 761 - 769, XP002632177, ISSN: 1095-9327 *
TAYLOR, L. D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295
TIBTECH, vol. 11, no. 5, May 1993 (1993-05-01), pages 155 - 215
TOLSTOSHEV, ANN. REV. PHARMACOL. TOXICOL., vol. 32, 1993, pages 573 - 596
TRICK ET AL., J. NEUROOPHTTHALMOL., vol. 26, 2006, pages 284 - 295
UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 1
URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534
WALLICK, S.C. ET AL., EXP. MED., vol. 168, 1988, pages 1099 - 1109
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WINNAKER: "From Genes to Clones", 1987, VERLAGSGESELLSCHAFT
WRIGHT, A. ET AL., EMBO J., vol. 10, 1991, pages 2717 - 2723
WU; WU, BIOTHERAPY, vol. 3, 1991, pages 87 - 95
WU; WU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432
YAMASHITA ET AL., CURR. OPIN. NEUROBIOL., vol. 17, 2007, pages 29 - 34

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9605069B2 (en) 2008-02-29 2017-03-28 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM a protein and uses thereof
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
US10822403B2 (en) 2011-12-14 2020-11-03 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CN107459576A (zh) * 2011-12-14 2017-12-12 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
RU2644337C2 (ru) * 2012-01-27 2018-02-08 Эббви Дойчланд Гмбх Унд Ко. Кг Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
US10106602B2 (en) 2012-01-27 2018-10-23 AbbVie Deutschland GmbH & Co. KG Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof
US9102722B2 (en) 2012-01-27 2015-08-11 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
KR20140125825A (ko) * 2012-01-27 2014-10-29 아비에 도이치란트 게엠베하 운트 콤파니 카게 신경돌기 변성과 연관된 질환의 진단 및 치료를 위한 조성물 및 방법
US9365643B2 (en) 2012-01-27 2016-06-14 AbbVie Deutschland GmbH & Co. KG Antibodies that bind to repulsive guidance molecule A (RGMA)
KR102129234B1 (ko) * 2012-01-27 2020-07-02 아비에 도이치란트 게엠베하 운트 콤파니 카게 신경돌기 변성과 연관된 질환의 진단 및 치료를 위한 조성물 및 방법
WO2013113107A1 (fr) * 2012-02-03 2013-08-08 University Health Network Procédés pour favoriser la survie neuronale, la croissance et/ou la régénération axonale
WO2015039212A1 (fr) * 2013-09-17 2015-03-26 University Health Network (Uhn): Technology Development And Commercialization Agents dirigés contre une interaction cis rgma/néogénine ou contre les radeaux lipidiques et utilisation de ceux-ci dans des méthodes thérapeutiques
US11497796B2 (en) 2013-09-17 2022-11-15 University Health Network Agents directed against a cis RGMa/neogenin interaction or lipid rafts and use of the same in methods of treatment
US10287346B2 (en) 2015-04-28 2019-05-14 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
EP3584260A1 (fr) * 2015-04-28 2019-12-25 Mitsubishi Tanabe Pharma Corporation Protéine de liaison à rgma et son utilisation
EP3290441A4 (fr) * 2015-04-28 2018-10-17 Mitsubishi Tanabe Pharma Corporation PROTÉINE DE LIAISON À RGMa ET SON UTILISATION
US11008388B2 (en) 2015-04-28 2021-05-18 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
IL287291B (en) * 2015-04-28 2022-09-01 Univ Osaka A protein that binds to rgma and its use
WO2019136043A1 (fr) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Protéines de fusion de co-recepteur à bras unique et utilisations associées

Also Published As

Publication number Publication date
JP2023075266A (ja) 2023-05-30
CA2780069A1 (fr) 2011-06-16
US20210277097A1 (en) 2021-09-09
US9175075B2 (en) 2015-11-03
PL2510001T3 (pl) 2016-06-30
SG181563A1 (en) 2012-07-30
ZA201204106B (en) 2013-02-27
JP2021100954A (ja) 2021-07-08
US20160075773A1 (en) 2016-03-17
KR20120118002A (ko) 2012-10-25
ES2562832T3 (es) 2016-03-08
EP2510001B1 (fr) 2015-12-02
JP6430438B2 (ja) 2018-11-28
IL219766A0 (en) 2012-07-31
EP2510001A1 (fr) 2012-10-17
CN102656190A (zh) 2012-09-05
DK2510001T3 (en) 2016-02-29
BR112012013734A2 (pt) 2017-01-10
MX2012006560A (es) 2012-10-05
US20110135664A1 (en) 2011-06-09
US20170114129A1 (en) 2017-04-27
JP2016198099A (ja) 2016-12-01
CN113717286A (zh) 2021-11-30
JP2013512942A (ja) 2013-04-18
JP5951498B2 (ja) 2016-07-13
JP2019059731A (ja) 2019-04-18
ECSP12012029A (es) 2012-08-31
CA2780069C (fr) 2018-07-17
AU2010329955A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
US20210277097A1 (en) Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
US20210230260A1 (en) Antibodies against the rgm a protein and uses thereof
AU2015200167A1 (en) Monoclonal antibodies against the RGM A protein and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080055275.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10794938

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 3539/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010329955

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2780069

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 219766

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2010329955

Country of ref document: AU

Date of ref document: 20101208

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12012501070

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2012542530

Country of ref document: JP

Ref document number: 000784-2012

Country of ref document: PE

Ref document number: MX/A/2012/006560

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201002632

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 2010794938

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2012-000350

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20127017655

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012128491

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012013734

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012013734

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120606